Summit Therapeutics (NASDAQ:SMMT – Get Free Report) had its price target lowered by research analysts at Barclays from $20.00 to $18.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price suggests a potential upside of 46.53% from the company’s current price.
SMMT has been the subject of several other reports. Morgan Stanley downgraded Summit Therapeutics to an “outperform” rating in a report on Tuesday, September 29th. Summit Redstone set a $25.00 price target on Summit Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Summit Therapeutics in a research report on Tuesday, September 22nd. Finally, UBS Group reiterated a “neutral” rating on shares of Summit Therapeutics in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.45.
Check Out Our Latest Analysis on Summit Therapeutics
Summit Therapeutics Stock Down 13.2%
Summit Therapeutics stock traded down $1.87 during mid-day trading on Monday, hitting $12.28. 9,824,309 shares of the company’s stock were exchanged, compared to its average volume of 4,668,601. The company’s 50 day simple moving average is $16.41 and its 200-day simple moving average is $16.14. The firm has a market capitalization of $9.82 billion, a P/E ratio of -11.57 and a beta of -1.49. Summit Therapeutics has a fifty-two week low of $11.94 and a fifty-two week high of $29.23.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Summit Therapeutics in the second quarter valued at approximately $138,838,000. Candriam S.C.A. increased its position in shares of Summit Therapeutics by 212.3% during the 3rd quarter. Candriam S.C.A. now owns 1,662,969 shares of the company’s stock worth $28,224,000 after purchasing an additional 1,130,537 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $12,603,000. The Manufacturers Life Insurance Company raised its stake in shares of Summit Therapeutics by 34.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company’s stock worth $11,240,000 after purchasing an additional 151,857 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of Summit Therapeutics during the 3rd quarter worth approximately $8,626,000. 4.61% of the stock is owned by institutional investors and hedge funds.
Latest Summit Therapeutics News
These are some of the SMMT news items that stood out recently:
- Neutral Sentiment: The company’s update confirms the FDA issued a CRL for ivonescimab with platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer. Investors will be watching for details on the FDA’s concerns and Summit’s next steps. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Negative Sentiment: The FDA setback to Summit’s lead cancer-drug application is the main catalyst weighing on SMMT. Reports said shares fell sharply, with one describing them at a 52-week low; the rejection delays the prospect of U.S. approval and adds risk to expectations for ivonescimab. Summit shares drop after US FDA declines to approve lung cancer drug Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Featured Stories
- Five stocks we like better than Summit Therapeutics
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
